VIVS

VivoSim Labs, Inc. (VIVS) - 10-Q Summary

Business Context and Reporting Period

This filing covers the quarterly period ended June 30, 2025. VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.) is a pharmaceutical and biotechnology services company focused on providing drug testing using 3D human tissue models of the liver and intestine. In March 2025, the Company sold its FXR314 inflammatory bowel disease (IBD) program to Eli Lilly for $10.0 million (with potential milestones up to $50.0 million) and shifted its primary focus to a services-based model offering toxicology insights. The Company changed its name to VivoSim Labs, Inc. effective April 24, 2025.

Key Financial Metrics

Note: All figures in thousands except per share data. Revenue consists entirely of royalty revenue from a license agreement with BICO Group AB. Product revenue was zero as the Mosaic division ceased operations.

Material Changes vs. Prior Period

• Revenue: Total revenue decreased slightly by $2,000 (5.1%) due to the cessation of product revenue, partially offset by a 48% increase in royalty revenue ($37k vs $25k).
• Expenses: Total operating expenses decreased by $473,000 (13.8%). Research and Development (R&D) expenses dropped 29% to $1.0 million, driven by a reduction in headcount (from 15 to 10 FTEs) and lower material costs. Selling, General, and Administrative (SG&A) expenses decreased 3% to $1.95 million.
• Liquidity: Cash and cash equivalents increased by approximately $2.9 million compared to the prior year period, primarily due to financing activities (ATM offerings) and the cash proceeds from the FXR program sale in the prior quarter, despite higher operating cash burn.
• Capital Structure: The Company issued 701,729 shares of common stock via its At-The-Market (ATM) facility during the quarter, generating net proceeds of approximately $1.8 million.

Outlook, Risks, and Contingencies

• Going Concern: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for at least one year following the issuance date. The Company expects to incur substantial additional operating losses and will require significant additional funding to support operations.
• Guidance: The Company expects total operating expenses for the fiscal year ending March 31, 2026, to be between $10 million and $11 million.
• Legal Contingencies: The Company is defending a lawsuit filed by H.C. Wainwright & Co., LLC alleging breach of a tail financing provision. As of June 30, 2025, the Company has accrued $0.6 million for this loss contingency ($0.4 million in accrued expenses and $0.2 million in equity-settled liability).
• Strategic Focus: The Company aims to have a product candidate for its Preclinical IBD Program ready for an Investigational New Drug (IND) application by December 2026. It is also leveraging FDA announcements favoring non-animal testing methods to expand its toxicology services.
• Financing Constraints: Due to a public float of less than $75.0 million, the Company is limited to raising one-third of its public float in primary public offerings over a 12-month period under Form S-3.

Investor Verification Checklist

• Verify the sufficiency of the $9.1 million cash balance against the projected $10-11 million annual operating burn rate and the timeline for securing additional capital.
• Confirm the status of the H.C. Wainwright litigation and the potential for additional accruals beyond the current $0.6 million reserve.
• Monitor the progress of the Preclinical IBD Program toward the December 2026 IND application target.
• Assess the impact of the Nasdaq Mandatory Panel Monitor regarding stockholders' equity compliance, which extends until April 30, 2026.
• Review the terms of the FXR314 asset sale to Eli Lilly to understand the probability and timing of the potential $50 million in milestone payments.